Tafamidis for transthyretin familial amyloid polyneuropathy

Autor: Coelho, Teresa, Maia, Luis F., Martins da Silva, Ana, Waddington Cruz, Marcia, Planté-Bordeneuve, Violaine, Lozeron, Pierre, Suhr, Ole B., Campistol, Josep M., Conceição, Isabel Maria, Schmidt, Hartmut H.-J., Trigo, Pedro, Kelly, Jeffery W., Labaudinière, Richard, Chan, Jason, Packman, Jeff, Wilson, Amy, Grogan, Donna R., Imventarza, Oscar C, Wainberg, Pablo J, Berra, Lucas M, Maultasch, Henryk, Gold, Jaime, Bardera, Juan Carlos Pare, Zibert, Andree
Zdroj: Neurology (Ovid); August 2012, Vol. 79 Issue: 8 p785-792, 8p
Abstrakt: To evaluate the efficacy and safety of 18 months of tafamidis treatment in patients with early-stage V30M transthyretin familial amyloid polyneuropathy (TTR-FAP).
Databáze: Supplemental Index